High Court Refuses Pfizer Appeal Over Novartis Hemophilia IP

Law360, New York (April 16, 2012, 12:00 PM EDT) -- The U.S. Supreme Court on Monday declined to hear a Pfizer Inc. unit's argument that a lower court incorrectly upheld Novartis Vaccines & Diagnostics Inc.'s hemophilia drug patents based based on a related but later invention.

The high court refused to grant a petition for certiorari filed by Genetics Institute LLC — a former subsidiary of Wyeth, which was purchased by Pfizer in 2009 — in which the company sought to have overturned last year's Federal Circuit ruling holding that the two Novartis patents were nonobvious...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.